• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

寻找卵巢癌免疫治疗反应的基因组生物标志物。

The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer.

机构信息

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

Clin Cancer Res. 2023 May 1;29(9):1645-1647. doi: 10.1158/1078-0432.CCR-23-0048.

DOI:10.1158/1078-0432.CCR-23-0048
PMID:36826422
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10159911/
Abstract

Immune checkpoint blockade has been ineffective in ovarian cancer, and there is an ongoing effort to identify biomarkers of therapeutic benefit. Despite promising preclinical data, a substudy of the IMagyn050 trial found that patients with homologous recombination deficient tumors did not have improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab. See related article by Landen et al., p. 1698.

摘要

免疫检查点阻断在卵巢癌中无效，目前正在努力寻找治疗获益的生物标志物。尽管有很有前景的临床前数据，但 IMagyn050 试验的一项亚研究发现，添加 PD-L1 抑制剂阿替利珠单抗并未改善同源重组缺陷肿瘤患者的无进展生存期。有关详情，参见 Landen 等人的文章第 1698 页。

相似文献

1
The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer.寻找卵巢癌免疫治疗反应的基因组生物标志物。
Clin Cancer Res. 2023 May 1;29(9):1645-1647. doi: 10.1158/1078-0432.CCR-23-0048.
2
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.基因组特征对新诊断卵巢癌免疫治疗的影响：来自 IMagyn050 随机临床试验的生物标志物分析。
Clin Cancer Res. 2023 May 1;29(9):1698-1707. doi: 10.1158/1078-0432.CCR-22-2032.
3
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).阿替利珠单抗、贝伐珠单抗联合化疗治疗新诊断的 III 期或 IV 期卵巢癌：安慰剂对照随机 III 期试验（IMagyn050/GOG 3015/ENGOT-OV39）。
J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23.
4
Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.全面分析鉴定 APOBEC3A 为卵巢癌中与基因组不稳定性相关的免疫预后生物标志物。
Front Immunol. 2021 Oct 21;12:749369. doi: 10.3389/fimmu.2021.749369. eCollection 2021.
5
Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.阿特珠单抗和贝伐珠单抗通过抑制上皮间质转化协同减轻顺铂耐药卵巢癌细胞的进展。
Front Immunol. 2019 Apr 26;10:867. doi: 10.3389/fimmu.2019.00867. eCollection 2019.
6
The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.卵巢癌免疫检查点阻断治疗的预测和预后生物标志物的现状。
Front Immunol. 2022 Oct 27;13:1045957. doi: 10.3389/fimmu.2022.1045957. eCollection 2022.
7
Biomarkers that may predict response to immunotherapy in ovarian malignancies.可能预测卵巢恶性肿瘤免疫治疗反应的生物标志物。
Curr Opin Obstet Gynecol. 2020 Feb;32(1):84-90. doi: 10.1097/GCO.0000000000000596.
8
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
9
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.综合基因组分析、肿瘤突变负担和 PD-L1 表达的整合，以鉴定非小细胞肺癌免疫治疗的新型生物标志物。
Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2.
10
Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.阿特珠单抗和 LncRNA PVT1 阻断协同通过 JAK2/STAT3/PD-L1 通路抑制顺铂耐药卵巢癌细胞的进展。
Clin Immunol. 2021 Jun;227:108728. doi: 10.1016/j.clim.2021.108728. Epub 2021 Apr 17.

引用本文的文献

1
Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy.针对 NF-κB 通路作为癌症免疫治疗中免疫检查点的潜在调节剂。
Cell Mol Life Sci. 2024 Feb 29;81(1):106. doi: 10.1007/s00018-023-05098-8.
2
New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer-A Systematic Review.难治性/复发性卵巢癌的分子生物学新进展及治疗选择——一项系统综述
Cancers (Basel). 2023 Nov 10;15(22):5356. doi: 10.3390/cancers15225356.
3
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.在新诊断的 III/IV 期卵巢癌中，阿替利珠单抗的安慰剂对照随机 III 期 IMagyn050/GOG 3015/ENGOT-OV39 试验的总生存和患者报告结局结果。
Gynecol Oncol. 2023 Oct;177:20-31. doi: 10.1016/j.ygyno.2023.06.018. Epub 2023 Aug 23.

本文引用的文献

1
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.基因组特征对新诊断卵巢癌免疫治疗的影响：来自 IMagyn050 随机临床试验的生物标志物分析。
Clin Cancer Res. 2023 May 1;29(9):1698-1707. doi: 10.1158/1078-0432.CCR-22-2032.
2
Therapeutic Development by Targeting the cGAS-STING Pathway in Autoimmune Disease and Cancer.通过靶向自身免疫性疾病和癌症中的cGAS-STING通路进行治疗性开发
Front Pharmacol. 2021 Nov 15;12:779425. doi: 10.3389/fphar.2021.779425. eCollection 2021.
3
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).阿替利珠单抗、贝伐珠单抗联合化疗治疗新诊断的 III 期或 IV 期卵巢癌：安慰剂对照随机 III 期试验（IMagyn050/GOG 3015/ENGOT-OV39）。
J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23.
4
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.帕博利珠单抗联合贝伐珠单抗和口服环磷酰胺节拍化疗治疗复发性卵巢癌的疗效和安全性：一项 2 期非随机临床试验。
JAMA Oncol. 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945.
5
Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer.复发性卵巢癌中的突变、同源DNA修复缺陷、肿瘤突变负荷及对免疫检查点抑制的反应
JCO Precis Oncol. 2020 Jun 16;4. doi: 10.1200/PO.20.00069. eCollection 2020.
6
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.随机 II 期试验：纳武利尤单抗对比纳武利尤单抗联合伊匹单抗用于复发性或持续性卵巢癌：NRG 肿瘤学研究。
J Clin Oncol. 2020 Jun 1;38(16):1814-1823. doi: 10.1200/JCO.19.02059. Epub 2020 Apr 10.
7
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.奥拉帕利联合贝伐珠单抗作为卵巢癌一线维持治疗。
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
8
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
9
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.尼拉帕利联合帕博利珠单抗治疗铂耐药复发性卵巢癌的单臂1/2期试验
JAMA Oncol. 2019 Aug 1;5(8):1141-1149. doi: 10.1001/jamaoncol.2019.1048.
10
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.阿维鲁单抗治疗复发性或难治性卵巢癌患者的疗效和安全性：JAVELIN 实体瘤试验的 1b 期结果。
JAMA Oncol. 2019 Mar 1;5(3):393-401. doi: 10.1001/jamaoncol.2018.6258.